法国人工智能初创公司Bioptimus近日宣布，其在成立不久后成功获得了3500万美元的种子轮融资，旨在构建一个专为生物技术设计的大型语言模型。此轮融资由法国知名生命科学风险投资公司Sofinnova Partners和公共银行Bpifrance Large Ventures共同领投，显示了投资者对Bioptimus创新理念的强烈信心。
参与本轮融资的还有法国风险投资公司Frst、全球投资机构Cathay Innovation，以及来自美国的投资者Headline和Owkin。值得一提的是，法国亿万富翁企业家Xavier Niel也加入了投资者行列，他的参与无疑为Bioptimus的发展注入了更多动力。
Bioptimus的这一举措标志着AI技术在生物科学领域的深入融合，有望开启生物技术研究的新篇章。通过利用先进的语言模型，公司旨在加速生物技术的研发进程，为医疗健康、药物发现等领域带来革命性的变化。
Sifted报道，Bioptimus的快速崛起和大规模融资，反映出市场对AI驱动的生物科学解决方案日益增长的需求。在生命科学和人工智能的交汇点，Bioptimus正积极构建一个创新平台，以解决传统生物技术面临的复杂问题。
此次种子轮融资的成功，将为Bioptimus提供必要的资金和资源，以推动其技术开发和市场拓展，同时也预示着AI在生物科学领域的广泛应用将加速推进。
英语如下：
**News Title:** “Bioptimus Raises $35 Million Seed Funding to Develop AI-driven BioScience Language Model”
**Keywords:** Bioptimus, seed round, $35 million
**News Content:**
**Startup Bioptimus Closes $35 Million Seed Funding Round, Pioneering a New Era in Biotechnology with AI**
French artificial intelligence (AI) startup Bioptimus recently announced that it has successfully secured a $35 million seed funding round shortly after its inception, aiming to develop a large language model tailored for the biotechnology sector. The round was co-led by prominent French life sciences venture capital firm Sofinnova Partners and public bank Bpifrance Large Ventures, demonstrating strong investor confidence in Bioptimus’s innovative vision.
Other participants in the financing round include French venture capital firm Frst, global investor Cathay Innovation, and American investors Headline and Owkin. Notably, French billionaire entrepreneur Xavier Niel has also joined the investor roster, injecting further momentum into Bioptimus’s growth.
Bioptimus’s move signifies a deep integration of AI technology in the biosciences, potentially ushering in a new chapter in biotechnology research. By leveraging advanced language models, the company aims to expedite the development of biotechnologies, revolutionizing sectors such as healthcare and drug discovery.
As reported by Sifted, Bioptimus’s rapid ascent and substantial funding reflect the growing demand for AI-driven solutions in the bio sciences field. At the intersection of life sciences and AI, Bioptimus is actively building an innovative platform to tackle complex issues faced by traditional biotechnology.
The successful seed round will provide Bioptimus with the necessary capital and resources to advance its technological development and market expansion, foreshadowing an acceleration in the widespread adoption of AI in the biosciences.
【来源】https://sifted.eu/articles/bioptimus-owkin-35m-seed
Views: 1